Malaysian Genomics Resource Centre Berhad (MGRC), through its wholly-owned subsidiary MGRC Therapeutics Sdn Bhd (“MGRCT”) has entered a Memorandum of Understanding (MoU) with Twistcode Technologies Sdn Bhd (Twistcode) to focus on the Bioinformatics Enhanced-Accelerated Services Terminal (B.E.A.S.T), a cutting-edge platform designed to revolutionise bioinformatics services across Malaysia and the Middle East.
MGRC, a leading genomics and biopharmaceutical specialist, said under the terms of the MoU, MGRCT and Twistcode will explore collaborative opportunities in research, development, and commercialisation. The partnership is poised to develop advanced bioinformatics tools and integrate artificial intelligence to accelerate bioinformatics processes, ultimately fostering a one-stop solution for bioinformatics services.
Malaysian Genomics Executive Chairman Azri Azerai said “We are keen to be with Twistcode to leverage their expertise in supercomputing and AI. This collaboration is set to enhance our capabilities in genomics and biopharmaceuticals significantly. Together, we aim to set new benchmarks in bioinformatics, contributing to advancements in healthcare and precision medicine.”
Twistcode Director Nurazan Malim said, “This MoU with MGRCT marks a significant milestone to harness the power of AI in healthcare. The B.E.A.S.T platform will not only enhance our technological capabilities but also create substantial value for the bioinformatics community.”
This strategic collaboration highlights MGRC’s commitment to spearheading innovation and transforming healthcare outcomes through advanced biotechnologies. By combining MGRC’s healthcare production capabilities with Twistcode computational expertise, this partnership is set to significantly advance the reach and effectiveness of bioinformatics services.
